

C30-A2  
Vol. 22 No. 17

Replaces C30-A  
Vol. 14 No. 12

---

## Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline—Second Edition

This document contains guidelines for performance of point-of-care (POC) blood glucose testing that stress quality control, training, and administrative responsibility.

---

A guideline for global application developed through the NCCLS consensus process.



# NCCLS...

## Serving the World's Medical Science Community Through Voluntary Consensus

NCCLS is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. NCCLS is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, NCCLS provides an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

### PUBLICATIONS

An NCCLS document is published as a standard, guideline, or committee report.

**Standard** A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

**Guideline** A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

**Report** A document that has not been subjected to consensus review and is released by the Board of Directors.

### CONSENSUS PROCESS

The NCCLS voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most NCCLS documents are subject to two levels of consensus—"proposed" and "approved." Depending on

the need for field evaluation or data collection, documents may also be made available for review at an intermediate (i.e., "tentative") consensus level.

**Proposed** An NCCLS consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

**Tentative** A tentative standard or guideline is made available for review and comment only when a recommended method has a well-defined need for a field evaluation or when a recommended protocol requires that specific data be collected. It should be reviewed to ensure its utility.

**Approved** An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

NCCLS standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following NCCLS's established consensus procedures. Provisions in NCCLS standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

### COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the NCCLS committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any NCCLS document. Address comments to the NCCLS Executive Offices, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

### VOLUNTEER PARTICIPATION

Healthcare professionals in all specialties are urged to volunteer for participation in NCCLS projects. Please contact the NCCLS Executive Offices for additional information on committee participation.

## Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline—Second Edition

### Abstract

NCCLS document C30-A2— *Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline— Second Edition* provides information for use by acute and chronic care facilities with laboratory support for structuring a point-of-care (POC) blood glucose testing service intended to ensure quality test results, as well as high-quality patient care. For facilities where laboratory support is not available, refer to NCCLS document AST4—*Blood Glucose Testing in Settings Without Laboratory Support*.

C30-A2 introduces policy-related issues with respect to administration of the program, persons who perform the tests, selection of methods, reporting of results, and the quality assurance aspects of point-of-care blood glucose testing. Also discussed are the uses of point-of-care blood glucose testing, authorization of operators, instrument verification, and procedural steps.

NCCLS. *Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline—Second Edition*. NCCLS document C30-A2 (ISBN 1-56238-471-6). NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.

THE NCCLS consensus process, which is the mechanism for moving a document through two or more levels of review by the healthcare community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of NCCLS documents. Current editions are listed in the *NCCLS Catalog*, which is distributed to member organizations, and to nonmembers on request. If your organization is not a member and would like to become one, and to request a copy of the *NCCLS Catalog*, contact the NCCLS Executive Offices. Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [exoffice@nccls.org](mailto:exoffice@nccls.org); Website: [www.nccls.org](http://www.nccls.org)



C30-A2  
ISBN 1-56238-471-6  
ISSN 0273-3099

---

## Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline—Second Edition

Volume 22 Number 17

David B. Sacks, M.D., Chairholder  
Patricia Bernhardt  
Louis J. Dunka, Jr., Ph.D.  
David E. Goldstein, M.D.  
Glen L. Hortin, M.D.  
Peter Mueller, Dr.rer.nat



This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system, transmitted, or made available in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from NCCLS, except as stated below.

NCCLS hereby grants permission to reproduce limited portions of this publication for use in laboratory procedure manuals at a single site, for interlibrary loan, or for use in educational programs provided that multiple copies of such reproduction shall include the following notice, be distributed without charge, and, in no event, contain more than 20% of the document's text.

Reproduced with permission, from NCCLS publication C30-A2—*Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline—Second Edition* (ISBN 1-56238-471-6). Copies of the current edition may be obtained from NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Permission to reproduce or otherwise use the text of this document to an extent that exceeds the exemptions granted here or under the Copyright Law must be obtained from NCCLS by written request. To request such permission, address inquiries to the Executive Director, NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Copyright ©2002. The National Committee for Clinical Laboratory Standards.

### **Suggested Citation**

(NCCLS. *Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline—Second Edition*. NCCLS document C30-A2 [ISBN 1-56238-471-6]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.)

### **Proposed Standard**

August 1989

### **Tentative Standard**

June 1991

### **Approved Standard**

September 1994

### **Approved Guideline—Second Edition**

August 2002

ISBN 1-56238-471-6

ISSN 0273-3099

## **Committee Membership**

### **Area Committee on Clinical Chemistry and Toxicology**

**W. Gregory Miller, Ph.D.**  
Chairholder

**Virginia Commonwealth University**  
**Richmond, Virginia**

**Thomas L. Williams, M.D.**  
Vice-Chairholder

**Methodist Hospital**  
**Omaha, Nebraska**

Paul D'Orazio, Ph.D.

Instrumentation Laboratory  
Lexington, Massachusetts

John H. Eckfeldt, M.D., Ph.D.

Fairview-University Medical Center  
Minneapolis, Minnesota

Susan A. Evans, Ph.D.

LifeScan, Inc.  
Milpitas, California

Neil Greenberg, Ph. D.

Ortho-Clinical Diagnostics  
Rochester, New York

Patrick J. Parsons, Ph.D.

New York State Dept. of Health  
Albany, New York

Noel V. Stanton, M.S.

WI State Laboratory of Hygiene  
Madison, Wisconsin

Thomas L. Williams, M.D.

Nebraska Methodist Hospital  
Omaha, Nebraska

### **Advisors**

Larry D. Bowers, Ph.D., DABCC

U.S. Anti-Doping Agency  
Colorado Springs, Colorado

George N. Bowers, Jr., M.D.

Hartford Hospital  
Hartford, Connecticut

Robert W. Burnett, Ph.D.

Hartford Hospital  
Farmington, Connecticut

Mary F. Burritt, Ph.D.

Mayo Clinic  
Rochester, Minnesota

Basil T. Doumas, Ph.D.

Medical College of Wisconsin  
Brookfield, Wisconsin

Kevin D. Fallon, Ph.D.

Instrumentation Laboratory  
Lexington, Massachusetts

Carl C. Garber, Ph.D.

Quest Diagnostics, Incorporated  
Teterboro, New Jersey

**Advisors (Continued)**

David E. Goldstein, M.D.	University of Missouri School of Medicine Columbia, Missouri
Gary A. Graham, Ph.D., DABCC	G2 Consulting Big Sandy, Texas
Harvey W. Kaufman, M.D.	Quest Diagnostics, Incorporated Teterboro, New Jersey
Richard R. Miller, Jr.	Dade Behring Inc. Newark, Delaware
Robert F. Moran, Ph.D., FCCM, FAIC	mvi Sciences Methuen, Massachusetts
David B. Sacks, M.D.	Brigham and Women's Hospital and Harvard Medical School Boston, Massachusetts
Bette Seamonds, Ph.D.	Mercy Health Laboratory Swarthmore, Pennsylvania
Professor Linda Thienpont	University of Ghent Ghent, Belgium
Hubert Vesper, Ph.D.	Centers for Disease Control and Prevention Atlanta, Georgia

**Working Group on Glucose**

<b>David B. Sacks, M.D.</b> <b>Chairholder</b>	<b>Brigham and Women's Hospital and Harvard Medical School Boston, Massachusetts</b>
Patricia Bernhardt	FDA Ctr. for Devices/Rad. Health Rockville, Maryland
Louis J. Dunka, Jr., Ph.D.	LifeScan, Inc. Milpitas, California
David E. Goldstein, M.D.	University of Missouri School of Medicine Columbia, Missouri
Glen L. Hortin, M.D.	National Institutes of Health Bethesda, Maryland
Peter Mueller, Dr.rer.nat	Roche Diagnostics GmbH Mannheim, Germany



**Advisors**

Carol A. Adiletto, M.S.	Inverness Medical Technology Waltham, Massachusetts
John Rex Astles, Ph.D.	Centers for Disease Control and Prevention Atlanta, Georgia
Roger R. Calam, Ph.D., DABCC	St. John Hospital and Medical Center Detroit, Michigan
Michael Flis	Roche Diagnostics Corporation Indianapolis, Indiana
Barry H. Ginsberg, M.D., Ph.D.	Becton Dickinson and Company Franklin Lakes, New Jersey
Olle Hagström	HemoCue AB Angelholm, Sweden
Joakim Hagvik	HemoCue AB Angelholm, Sweden
Ellis Jacobs, Ph.D., DABCC, FACB	The Mt. Sinai Hospital-NYU Medical Center New York, New York
Frederick L. Kiechle, M.D., Ph.D.	William Beaumont Hospital Royal Oak, Michigan
Richard J. Naples	Roche Diagnostics Corporation Indianapolis, Indiana
Ronald H. Ng, Ph.D.	Abbott Laboratories, MediSense Products Bedford, Massachusetts
Donald R. Parker, Ph.D.	Bayer Corporation Elkart, Indiana
Ann Tideman	Bayer Corporation Elkhart, Indiana
Bryan K. Vail, M.T.(ASCP)	VA Milwaukee Medical Center Milwaukee, Wisconsin
Jennifer K. McGeary, M.T.(ASCP), M.S.H.A. <i>Staff Liaison</i>	NCCLS Wayne, Pennsylvania
Patrice E. Polgar <i>Editor</i>	NCCLS Wayne, Pennsylvania
Donna M. Wilhelm <i>Assistant Editor</i>	NCCLS Wayne, Pennsylvania

## **Acknowledgement**

The Area Committee on Clinical Chemistry and Toxicology would like to recognize the valuable contributions of the members and advisors of the Subcommittee on Ancillary Blood Glucose Testing that developed the first approved edition of this guideline.

Judith T. Barr, Sc.D., Chairholder  
Jean Betschart, M.N., R.N., C.D.E.  
Alfred Bracey, M.A.  
Frederick L. Kiechle, M.D., Ph.D.  
Marlene J. Koch, M.T., (ASCP)  
Robert Metz, M.D., Ph.D.  
Kathryn Mulcahy, R.N., M.S.N., C.D.E.  
Nina Peled, Ph.D.  
Steven J. Quinlan

## **Advisors**

Daniel M. Baer, M.D.  
Joan Kenny Bardsley  
Sue Bogner, Ph.D.  
Mary G. Day, M.T.(ASCP)  
Jan Gagen  
Mary Anne Gardineer  
Barry H. Ginsberg, M.D., Ph.D.  
June M. Gregonis  
Linda Haas  
Mary Tabb Johnston  
Pauline Y. Lau, Ph.D.  
Kenneth D. McClatchey, M.D., D.D.S.  
Robert F. Moran, Ph.D., F.C.C.M., FAIC  
Carol V. Nelson  
Elizabeth G. Outlaw, M.T.  
Aubrey S. Outschoorn, Ph.D.  
Theodore J. Passon, Jr., Ph.D.  
Christyne C. Price  
Norman Pritchard  
Robert Rej, Ph.D.  
Dr. Richard E. Scott  
Bette Seamonds, Ph.D.  
Mary M. Stitak  
Diana Trundle, Ph.D.  
Dr. Stupidike

## Active Membership (as of 1 July 2002)

### Sustaining Members

Abbott Laboratories  
 American Association for  
 Clinical Chemistry  
 Beckman Coulter, Inc.  
 BD and Company  
 bioMérieux, Inc.  
 CLMA  
 College of American Pathologists  
 GlaxoSmithKline  
 Nippon Becton Dickinson Co., Ltd.  
 Ortho-Clinical Diagnostics, Inc.  
 Pfizer Inc  
 Roche Diagnostics, Inc.

### Professional Members

AISAR-Associazione Italiana per lo  
 Studio degli  
 American Academy of Family  
 Physicians  
 American Association for  
 Clinical Chemistry  
 American Association for  
 Respiratory Care  
 American Chemical Society  
 American Medical Technologists  
 American Public Health Association  
 American Society for Clinical  
 Laboratory Science  
 American Society of Hematology  
 American Society for Microbiology  
 American Type Culture  
 Collection, Inc.  
 Asociación Española Primera de  
 Socorros (Uruguay)  
 Asociacion Mexicana de  
 Bioquímica Clínica A.C.  
 Assn. of Public Health Laboratories  
 Assoc. Micro. Clinici Italiani-  
 A.M.C.L.I.  
 British Society for Antimicrobial  
 Chemotherapy  
 CADIME-Camara De Instituciones  
 De Diagnostico Medico  
 Canadian Society for Medical  
 Laboratory Science—Société  
 Canadienne de Science de  
 Laboratoire Médical  
 Clinical Laboratory Management  
 Association  
 COLA  
 College of American Pathologists

College of Medical Laboratory  
 Technologists of Ontario  
 College of Physicians and  
 Surgeons of Saskatchewan  
 ESCMID  
 Fundación Bioquímica Argentina  
 International Association of Medical  
 Laboratory Technologists  
 International Council for  
 Standardization in Haematology  
 International Federation of  
 Clinical Chemistry  
 Italian Society of Clinical  
 Biochemistry and Clinical  
 Molecular Biology  
 Japan Society of Clinical Chemistry  
 Japanese Committee for Clinical  
 Laboratory Standards  
 Joint Commission on Accreditation  
 of Healthcare Organizations  
 National Academy of Clinical  
 Biochemistry  
 National Association of Testing  
 Authorities – Australia  
 National Society for  
 Histotechnology, Inc.  
 Ontario Medical Association  
 Quality Management Program-  
 Laboratory Service  
 RCPA Quality Assurance Programs  
 PTY Limited  
 Sociedade Brasileira de Analises  
 Clinicas  
 Sociedade Brasileira de  
 Patologia Clinica  
 Sociedad Espanola de Bioquímica  
 Clinica y Patologia Molecular  
 Turkish Society of Microbiology

### Government Members

Association of Public Health  
 Laboratories  
 Armed Forces Institute of Pathology  
 BC Centre for Disease Control  
 Centers for Disease Control and  
 Prevention  
 Centers for Medicare & Medicaid  
 Services/CLIA Program  
 Centers for Medicare & Medicaid  
 Services  
 Chinese Committee for Clinical  
 Laboratory Standards  
 Commonwealth of Pennsylvania  
 Bureau of Laboratories

Department of Veterans Affairs  
 Deutsches Institut für Normung  
 (DIN)  
 FDA Center for Devices and  
 Radiological Health  
 FDA Center for Veterinary  
 Medicine  
 FDA Division of Anti-Infective  
 Drug Products  
 Iowa State Hygienic Laboratory  
 Massachusetts Department of  
 Public Health Laboratories  
 National Center of Infectious  
 and Parasitic Diseases (Bulgaria)  
 National Health Laboratory Service  
 (South Africa)  
 National Institute of Standards  
 and Technology  
 New York State Department of  
 Health  
 Ohio Department of Health  
 Ontario Ministry of Health  
 Pennsylvania Dept. of Health  
 Saskatchewan Health-Provincial  
 Laboratory  
 Scientific Institute of Public Health;  
 Belgium Ministry of Social  
 Affairs, Public Health and the  
 Environment  
 Swedish Institute for Infectious  
 Disease Control  
 Thailand Department of Medical  
 Sciences

### Industry Members

AB Biodisk  
 Abbott Laboratories  
 Abbott Laboratories, MediSense  
 Products  
 Acrometrix Corporation  
 Ammirati Regulatory Consulting  
 Anaerobe Systems  
 Assessor  
 AstraZeneca  
 AstraZeneca R & D  
 Boston  
 Aventis  
 Axis-Shield POC AS  
 Bayer Corporation – Elkhart, IN  
 Bayer Corporation – Tarrytown, NY  
 Bayer Corporation – West Haven,  
 CT  
 Bayer Medical Ltd.  
 BD

BD Biosciences – San Jose, CA  
 BD Consumer Products  
 BD Diagnostic Systems  
 BD Italia S.P.A.  
 BD VACUTAINER Systems  
 Beckman Coulter, Inc.  
 Beckman Coulter, Inc. Primary Care Diagnostics  
 Beckman Coulter K.K. (Japan)  
 Bio-Development SRL  
 Bio-Inova Life Sciences International  
 Bio-Inova Life Sciences North America  
 BioMedia Laboratories Sdn Bhd  
 BioMérieux (NC)  
 bioMérieux, Inc. (MO)  
 Biometrology Consultants  
 Bio-Rad Laboratories, Inc.  
 Bio-Rad Laboratories, Inc. - France  
 Biotest AG  
 Blaine Healthcare Associates, Inc.  
 Bristol-Myers Squibb Company  
 Canadian External Quality Assessment Laboratory  
 Capital Management Consulting, Inc.  
 Carl Schaper  
 Checkpoint Development Inc.  
 Chiron Corporation  
 ChromaVision Medical Systems, Inc.  
 Chronolab Ag  
 Clinical Design Group Inc.  
 Clinical Laboratory Improvement Consultants  
 Cognigen  
 Community Medical Center (NJ)  
 Control Lab (Brazil)  
 Copan Diagnostics Inc.  
 Cosmetic Ingredient Review  
 Cubist Pharmaceuticals  
 Dade Behring Inc. - Deerfield, IL  
 Dade Behring Inc. - Glasgow, DE  
 Dade Behring Inc. - Marburg, Germany  
 Dade Behring Inc. - Sacramento, CA  
 Dade Behring Inc. - San Jose, CA  
 David G. Rhoads Associates, Inc.  
 Diagnostics Consultancy  
 Diagnostic Products Corporation  
 Eiken Chemical Company, Ltd.  
 Elan Pharmaceuticals  
 Electa Lab s.r.l.  
 Enterprise Analysis Corporation  
 Essential Therapeutics, Inc.  
 EXPERTech Associates, Inc.  
 F. Hoffman-La Roche AG  
 Fort Dodge Animal Health

General Hospital Vienna (Austria)  
 Gen-Probe  
 GlaxoSmithKline  
 Greiner Bio-One Inc.  
 Helena Laboratories  
 Home Diagnostics, Inc.  
 Immunicon Corporation  
 Instrumentation Laboratory  
 International Technidyne Corporation  
 IntraBiotics Pharmaceuticals, Inc.  
 I-STAT Corporation  
 Johnson and Johnson Pharmaceutical Research and Development, L.L.C.  
 Kendall Sherwood-Davis & Geck  
 LAB-Interlink, Inc.  
 Laboratory Specialists, Inc.  
 Labtest Diagnostica S.A.  
 LifeScan, Inc. (a Johnson & Johnson Company)  
 Lilly Research Laboratories  
 Macemon Consultants  
 Medical Device Consultants, Inc.  
 Merck & Company, Inc.  
 Minigrip/Zip-Pak  
 Molecular Diagnostics, Inc.  
 mvi Sciences (MA)  
 Nabi  
 Nichols Institute Diagnostics (Div. of Quest Diagnostics, Inc.)  
 NimbleGen Systems, Inc.  
 Nissui Pharmaceutical Co., Ltd.  
 Nippon Becton Dickinson Co., Ltd.  
 Norfolk Associates, Inc.  
 Novartis Pharmaceuticals Corporation  
 Ortho-Clinical Diagnostics, Inc. (Raritan, NJ)  
 Ortho-Clinical Diagnostics, Inc. (Rochester, NY)  
 Oxoid Inc.  
 Paratek Pharmaceuticals  
 Pfizer Inc  
 Pharmacia Corporation  
 Philips Medical Systems  
 Powers Consulting Services  
 Premier Inc.  
 Procter & Gamble Pharmaceuticals, Inc.  
 The Product Development Group  
 QSE Consulting  
 Quintiles, Inc.  
 Radiometer America, Inc.  
 Radiometer Medical A/S  
 Roche Diagnostics GmbH  
 Roche Diagnostics, Inc.  
 Roche Laboratories (Div. Hoffmann-La Roche Inc.)  
 Sarstedt, Inc.

SARL Laboratoire Carron (France)  
 Schering Corporation  
 Schleicher & Schuell, Inc.  
 Second Opinion  
 Showa Yakuhin Kako Company, Ltd.  
 Streck Laboratories, Inc.  
 SurroMed, Inc.  
 Synermed Diagnostic Corp.  
 Sysmex Corporation (Japan)  
 Sysmex Corporation (Long Grove, IL)  
 The Clinical Microbiology Institute  
 The Toledo Hospital (OH)  
 Theravance Inc.  
 Transasia Engineers  
 Trek Diagnostic Systems, Inc.  
 Versicor, Inc.  
 Vetoquinol S.A.  
 Visible Genetics, Inc.  
 Vysis, Inc.  
 Wallac Oy  
 Wyeth-Ayerst  
 Xyletech Systems, Inc.  
 YD Consultant  
 YD Diagnostics (Seoul, Korea)

**Trade Associations**

AdvaMed  
 Association of Medical Diagnostic Manufacturers  
 Japan Association Clinical Reagents Ind. (Tokyo, Japan)  
 Medical Industry Association of Australia

**Associate Active Members**

20<sup>th</sup> Medical Group (SC)  
 31<sup>st</sup> Medical Group/SGSL (APO, AE)  
 67<sup>th</sup> CSH Wuerzburg, GE (NY)  
 121<sup>st</sup> General Hospital (CA)  
 Academisch Ziekenhuis-VUB (Belgium)  
 Acadiana Medical Laboratories, LTD (LA)  
 Adena Regional Medical Center (OH)  
 Advocate Healthcare Lutheran General (IL)  
 Akershus Central Hospital and AFA (Norway)  
 Albemarle Hospital (NC)  
 Allegheny General Hospital (PA)  
 Allegheny University of the Health Sciences (PA)  
 Allina Health System (MN)

Alton Ochsner Medical Foundation (LA)	Clinical Laboratory Partners, LLC (CT)	Geisinger Medical Center (PA)
American Medical Laboratories (VA)	CLSI Laboratories (PA)	Grady Memorial Hospital (GA)
Antwerp University Hospital (Belgium)	Columbia Regional Hospital (MO)	Guthrie Clinic Laboratories (PA)
Arkansas Department of Health	Commonwealth of Kentucky	Hahnemann University Hospital (PA)
ARUP at University Hospital (UT)	Community Hospital of Lancaster (PA)	Harris Methodist Erath County (TX)
Armed Forces Research Institute of Medical Science (APO, AP)	CompuNet Clinical Laboratories (OH)	Harris Methodist Fort Worth (TX)
Associated Regional & University Pathologists (UT)	Cook County Hospital (IL)	Hartford Hospital (CT)
Aurora Consolidated Laboratories (WI)	Cook Children's Medical Center (TX)	Headwaters Health Authority (Alberta, Canada)
Azienda Ospedale Di Lecco (Italy)	Covance Central Laboratory Services (IN)	Health Network Lab (PA)
Bay Medical Center (MI)	Danish Veterinary Laboratory (Denmark)	Health Partners Laboratories (VA)
Baystate Medical Center (MA)	Danville Regional Medical Center (VA)	Heartland Regional Medical Center (MO)
Bbaguas Duzen Laboratories (Turkey)	Delaware Public Health Laboratory	Highlands Regional Medical Center (FL)
Bermuda Hospitals Board	Department of Health & Community Services (New Brunswick, Canada)	Hoag Memorial Hospital Presbyterian (CA)
Bo Ali Hospital (Iran)	DesPeres Hospital (MO)	Holmes Regional Medical Center (FL)
British Columbia Cancer Agency (Vancouver, BC, Canada)	DeTar Hospital (TX)	Holzer Medical Center (OH)
Brooks Air Force Base (TX)	Detroit Health Department (MI)	Hopital du Sacre-Coeur de Montreal (Montreal, Quebec, Canada)
Broward General Medical Center (FL)	Diagnosticos da América S/A (Brazil)	Hôpital Maisonneuve – Rosemont (Montreal, Canada)
Calgary Laboratory Services	Dr. Everett Chalmers Hospital (New Brunswick, Canada)	Hospital for Sick Children (Toronto, ON, Canada)
Carilion Consolidated Laboratory (VA)	Doctors Hospital (Bahamas)	Hospital Sousa Martins (Portugal)
Cathay General Hospital (Taiwan)	Duke University Medical Center (NC)	Hotel Dieu Hospital (Windsor, ON, Canada)
CB Healthcare Complex (Sydney, NS, Canada)	E.A. Conway Medical Center (LA)	Houston Medical Center (GA)
Central Peninsula General Hospital (AK)	Eastern Maine Medical Center	Huddinge University Hospital (Sweden)
Central Texas Veterans Health Care System	East Side Clinical Laboratory (RI)	Hurley Medical Center (MI)
Centre Hospitalier Regional del la Citadelle (Belgium)	Eastern Health (Vic., Australia)	Indiana State Board of Health
Centro Diagnostico Italiano (Milano, Italy)	Elyria Memorial Hospital (OH)	Indiana University
Champlain Valley Physicians Hospital (NY)	Emory University Hospital (GA)	Institute of Medical and Veterinary Science (Australia)
Chang Gung Memorial Hospital (Taiwan)	Esoterix Center for Infectious Disease (TX)	International Health Management Associates, Inc. (IL)
Changi General Hospital (Singapore)	Fairview-University Medical Center (MN)	Jackson Memorial Hospital (FL)
Children's Hospital (NE)	Federal Medical Center (MN)	Jersey Shore Medical Center (NJ)
Children's Hospital & Clinics (MN)	Florida Hospital East Orlando	John C. Lincoln Hospital (AZ)
Children's Hospital Medical Center (Akron, OH)	Foothills Hospital (Calgary, AB, Canada)	John F. Kennedy Medical Center (NJ)
Children's Hospital of Philadelphia (PA)	Fort St. John General Hospital (Fort St. John, BC, Canada)	John Peter Smith Hospital (TX)
Children's Medical Center of Dallas (TX)	Fox Chase Cancer Center (PA)	Kadlec Medical Center (WA)
Clarian Health–Methodist Hospital (IN)	Fresenius Medical Care/Spectra East (NJ)	Kaiser Permanente Medical Care (CA)
Clendo Lab (Puerto Rico)	Fresno Community Hospital and Medical Center	Kaiser Permanente (MD)
	Frye Regional Medical Center (NC)	Kantonsspital (Switzerland)
	Gambro Healthcare Laboratory Services (FL)	Keller Army Community Hospital (NY)
	Gateway Medical Center (TN)	Kenora-Rainy River Regional Laboratory Program (Ontario, Canada)

Kern Medical Center (CA)	Michigan Department of Community Health	Regions Hospital
Kimball Medical Center (NJ)	Mississippi Baptist Medical Center	Reid Hospital & Health Care Services (IN)
King Faisal Specialist Hospital (Saudi Arabia)	Monte Tabor – Centro Italo - Brazileiro de Promocao (Brazil)	Research Medical Center (MO)
King Khalid National Guard Hospital (Saudi Arabia)	Montreal Children’s Hospital (Canada)	Rex Healthcare (NC)
King’s Daughter Medical Center (KY)	Montreal General Hospital (Canada)	Rhode Island Department of Health Laboratories
Klinični Center (Slovenia)	MRL Pharmaceutical Services, Inc. (VA)	Riyadh Armed Forces Hospital (Saudi Arabia)
Laboratories at Bonfils (CO)	MRL Reference Laboratory (CA)	Royal Columbian Hospital (New Westminster, BC, Canada)
Laboratoire de Santé Publique du Quebec (Canada)	Nassau County Medical Center (NY)	Sacred Heart Hospital (MD)
Laboratório Fleury S/C Ltda. (Brazil)	National Institutes of Health (MD)	Saint Mary’s Regional Medical Center (NV)
Laboratory Corporation of America (NJ)	Naval Hospital – Corpus Christi (TX)	St. Alexius Medical Center (ND)
Laboratory Corporation of America (MO)	Naval Surface Warfare Center (IN)	St. Anthony Hospital (CO)
LAC and USC Healthcare Network (CA)	Nebraska Health System	St. Anthony’s Hospital (FL)
Lakeland Regional Medical Center (FL)	New Britain General Hospital (CT)	St. Barnabas Medical Center (NJ)
Lancaster General Hospital (PA)	New England Fertility Institute (CT)	St-Eustache Hospital (Quebec, Canada)
Langley Air Force Base (VA)	New Mexico VA Health Care System	St. Francis Medical Ctr. (CA)
LeBonheur Children’s Medical Center (TN)	North Carolina State Laboratory of Public Health	St. John Hospital and Medical Center (MI)
L’Hotel-Dieu de Quebec (Canada)	North Kansas City Hospital (MO)	St. John Hospital and Medical Center (MI)
Libero Istituto Univ. Campus BioMedico (Italy)	North Shore – Long Island Jewish Health System Laboratories (NY)	St. John Regional Hospital (St. John, NB, Canada)
Louisiana State University Medical Center	Northwestern Memorial Hospital (IL)	St. Joseph Hospital (NE)
Maccabi Medical Care and Health Fund (Israel)	O.L. Vrouwziekenhuis (Belgium)	St. Joseph’s Hospital – Marshfield Clinic (WI)
Magee Womens Hospital (PA)	Ordre professionnel des technologistes médicaux du Québec	St. Joseph Mercy Hospital (MI)
Malcolm Grow USAF Medical Center (MD)	Ospedali Riuniti (Italy)	St. Jude Children's Research Hospital (TN)
Manitoba Health (Winnipeg, Canada)	The Ottawa Hospital (Ottawa, ON, Canada)	St. Luke’s Regional Medical Center (IA)
Martin Luther King/Drew Medical Center (CA)	Our Lady of Lourdes Hospital (NJ)	St. Mary of the Plains Hospital (TX)
Massachusetts General Hospital (Microbiology Laboratory)	Our Lady of the Resurrection Medical Center (IL)	St. Mary’s Hospital & Medical Center (CO)
MDS Metro Laboratory Services (Burnaby, BC, Canada)	Pathology and Cytology Laboratories, Inc. (KY)	St. Mary’s Hospital (Vancouver, BC, Montreal)
Medical College of Virginia Hospital	The Permanente Medical Group (CA)	St. Vincent Medical Center (CA)
Medicare/Medicaid Certification, State of North Carolina	Piedmont Hospital (GA)	Ste. Justine Hospital (Montreal, PQ, Canada)
Memorial Medical Center (IL)	Pikeville Methodist Hospital (KY)	Salina Regional Health Center (KS)
Memorial Medical Center (LA) Jefferson Davis Hwy	Pocono Hospital (PA)	San Francisco General Hospital (CA)
Memorial Medical Center (LA) Napoleon Avenue	Presbyterian Hospital of Dallas (TX)	San Francisco General Hospital (CA)
Methodist Hospital (TX)	Queen Elizabeth Hospital (Prince Edward Island, Canada)	Santa Clara Valley Medical Center (CA)
Methodist Hospitals of Memphis (TN)	Queensland Health Pathology Services (Australia)	Santa Clara Valley Medical Center (CA)
MetroHealth Medical Center (OH)	Quest Diagnostics Incorporated (CA)	Seoul Nat’l University Hospital (Korea)
	Quintiles Laboratories, Ltd. (GA)	Shanghai Center for the Clinical Laboratory (China)
		South Bend Medical Foundation (IN)
		Southwest Texas Methodist Hospital (TX)
		South Western Area Pathology Service (Australia)
		Southern Maine Medical Center

Specialty Laboratories, Inc. (CA)  
 Stanford Hospital and Clinics (CA)  
 State of Washington Department of Health  
 Stony Brook University Hospital (NY)  
 Stormont-Vail Regional Medical Center (KS)  
 Sun Health-Boswell Hospital (AZ)  
 Sunrise Hospital and Medical Center (NV)  
 Swedish Medical Center – Providence Campus (WA)  
 Tampa General Hospital (FL)  
 Temple University Hospital (PA)  
 Tenet Odessa Regional Hospital (TX)  
 The Toledo Hospital (OH)  
 Touro Infirmary (LA)  
 Trident Regional Medical Center (SC)  
 Tripler Army Medical Center (HI)  
 Truman Medical Center (MO)  
 UCSF Medical Center (CA)  
 UNC Hospitals (NC)  
 University College Hospital (Galway, Ireland)

University Hospital (Gent) (Belgium)  
 University Hospitals of Cleveland (OH)  
 The University Hospitals (OK)  
 University of Alabama-Birmingham Hospital  
 University of Alberta Hospitals (Canada)  
 University of Colorado Health Science Center  
 University of Chicago Hospitals (IL)  
 University of Illinois Medical Center  
 University of the Ryukyus (Japan)  
 University of Texas M.D. Anderson Cancer Center  
 University of Virginia Medical Center  
 University of Washington  
 UZ-KUL Medical Center (Belgium)  
 VA (Denver) Medical Center (CO)  
 Virginia Department of Health  
 VA (Kansas City) Medical Center (MO)  
 VA (Western NY) Healthcare System

VA (San Diego) Medical Center (CA)  
 VA (Tuskegee) Medical Center (AL)  
 VA Outpatient Clinic (OH)  
 Vejle Hospital (Denmark)  
 Washington Adventist Hospital (MD)  
 Washoe Medical Center Laboratory (NV)  
 West Jefferson Medical Center (LA)  
 West Shore Medical Center (MI)  
 Wilford Hall Medical Center (TX)  
 William Beaumont Army Medical Center (TX)  
 William Beaumont Hospital (MI)  
 Williamsburg Community Hospital (VA)  
 Winn Army Community Hospital (GA)  
 Winnipeg Regional Health Authority (Winnipeg, Canada)  
 Wishard Memorial Hospital (IN)  
 Yonsei University College of Medicine (Korea)  
 York Hospital (PA)

**OFFICERS**

Donna M. Meyer, Ph.D.,  
 President  
 CHRISTUS Health

Thomas L. Hearn, Ph.D.,  
 President Elect  
 Centers for Disease Control and Prevention

Emil Voelkert, Ph.D.,  
 Secretary  
 Roche Diagnostics GmbH

Gerald A. Hoeltge, M.D.,  
 Treasurer  
 The Cleveland Clinic Foundation

F. Alan Andersen, Ph.D.,  
 Immediate Past President  
 Cosmetic Ingredient Review

John V. Bergen, Ph.D.,  
 Executive Director

**BOARD OF DIRECTORS**

Susan Blonshine, RRT, RPFT,  
 FAARC  
 TechEd

Wayne Brinster  
 BD

Kurt H. Davis, FCSMLS, CAE  
 Canadian Society for Medical Laboratory Science

Lillian J. Gill, M.S.  
 FDA Center for Devices and Radiological Health

Robert L. Habig, Ph.D.  
 Habig Consulting Group

Carolyn D. Jones, J.D., M.P.H.  
 AdvaMed

Tadashi Kawai, M.D., Ph.D.  
 International Clinical Pathology Center

J. Stephen Kroger, M.D., FACP  
 COLA

Willie E. May, Ph.D.  
 National Institute of Standards and Technology

Gary L. Myers, Ph.D.  
 Centers for Disease Control and Prevention

Barbara G. Painter, Ph.D.  
 Bayer Corporation (Retired)

Judith A. Yost, M.A., M.T.(ASCP)  
 Centers for Medicare & Medicaid Services





**Contents**

Abstract ..... i

Committee Membership ..... v

Active Membership ..... ix

Foreword ..... xvii

The Quality System Approach ..... xviii

1 Introduction ..... 1

    1.1 Scope ..... 1

2 Definitions ..... 1

3 Policy ..... 2

    3.1 Administration ..... 2

    3.2 Persons Who Perform the Tests ..... 2

    3.3 Methods ..... 3

    3.4 Results ..... 3

    3.5 Quality Assurance (QA) ..... 3

4 Appropriate Uses of POC Blood Glucose Testing ..... 3

    4.1 Applications ..... 3

    4.2 Limitations ..... 4

    4.3 Areas of Use ..... 4

5 Administration ..... 4

    5.1 Designation of Responsibility ..... 4

    5.2 Coordination of Services ..... 5

6 Performance Demonstration of POC Blood Glucose Monitoring System ..... 5

    6.1 Initial Performance Demonstration ..... 5

    6.2 Demonstration of Performance of Additional Glucose Monitors ..... 5

    6.3 Comparing Results between the POC Blood Glucose Monitoring System  
    and a Laboratory Instrument ..... 5

7 Quality Assurance Program ..... 8

    7.1 Quality Assurance Log ..... 8

    7.2 QC ..... 9

    7.3 Maintenance and Service ..... 9

    7.4 Proficiency Testing ..... 10

8 Procedure ..... 10

    8.1 Procedure Manual ..... 10

    8.2 Specimen Collection ..... 10

    8.3 Instrument Calibration ..... 12

    8.4 Test Procedure ..... 12

    8.5 Results ..... 12

**Contents (Continued)**

9 Institutional Authorization Process.....13

    9.1 Training Program.....13

    9.2 Demonstration of Operator Competency for POC Blood Glucose Testing.....14

    9.3 Continuing Authorization.....14

    9.4 Withdrawal of POC Blood Glucose Testing Authorization .....14

References.....15

Summary of Comments and Working Group Responses .....16

Summary of Delegate Comments and Working Group Responses .....18

Related NCCLS Publications.....20

## Foreword

When rapid results are required for medical staff members to make therapeutic decisions, and the time required to obtain results from the clinical laboratory would compromise patient care, point-of-care (POC) blood glucose testing is appropriate. Note, however, that this type of testing supplements, rather than substitutes for, testing in the clinical laboratory.

Designing a POC blood glucose testing service requires the close and active collaboration of many departments within the user institution. The primary focus of responsibility for POC blood glucose testing may vary with the specific needs of each institution.

Guidelines for all aspects of a POC blood glucose testing service are presented in this document. The committee believes that a facility must consider all of the recommendations within this document when developing a POC blood glucose testing service. Individual users must demonstrate their ability to operate instruments and perform quality assurance (QA) procedures. Strict adherence to procedures as recommended by the manufacturers must be observed.

Readers of this document are cautioned to monitor changes in laboratory regulations so that POC blood glucose testing procedures can be modified to comply with new requirements.

## Standard Precautions

Because it is often impossible to know what might be infectious, all human blood specimens are to be treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of any pathogen and are thus more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard precaution and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (*Guideline for Isolation Precautions in Hospitals*. Infection Control and Hospital Epidemiology. CDC. 1996;Vol 17;1:53-80), (MMWR 1987;36[suppl 2S]2S-18S), and (MMWR 1988;37:377-382, 387-388). For specific precautions for preventing the laboratory transmission of blood-borne infection from laboratory instruments and materials and for recommendations for the management of blood-borne exposure, refer to NCCLS document M29—*Protection of Laboratory Workers from Occupationally Acquired Infections*.

## Key Words

Authorization, blood glucose, diabetes, operator, point-of-care (POC) testing, training, verification

## The Quality System Approach

NCCLS subscribes to a quality system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents through a gap analysis. The approach is based on the model presented in the most current edition of NCCLS HS1- *A Quality System Model for Health Care*. The quality system approach applies a core set of “quality system essentials (QSEs),” basic to any organization, to all operations in any healthcare service’s path of workflow. The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The quality system essentials (QSEs) are:

QSEs	
Documents & Records	Information Management
Organization	Occurrence Management
Personnel	Assessment
Equipment	Process Improvement
Purchasing & Inventory	Service & Satisfaction
Process Control	Facilities & Safety


### C30-A2 Addresses the Following Quality System Essentials (QSEs)

Documents & Records	Organization	Personnel	Equipment	Purchasing & Inventory	Process Control	Information Management	Occurrence Management	Assessment	Process Improvement	Service & Satisfaction	Facilities & Safety
X		X			X						

Adapted from NCCLS document HS1— *A Quality System Model for Health Care*

### Path of Workflow

A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, GP26-A2 defines a clinical laboratory path of workflow that consists of three sequential processes: preanalytical, analytical, and postanalytical. All clinical laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information. The arrow depicts the sequence, from left to right, that any clinical laboratory follows. In addition, the necessary steps or subprocesses are listed below them.



Adapted from NCCLS document HS1— *A Quality System Model for Health Care*

Most of NCCLS's documents relate to the clinical laboratory, so the most common path of workflow will be that depicted above. The path of workflow for other healthcare activities, e.g., respiratory services, imaging services, etc., or for other types of organizations, e.g., medical device manufacturers, will differ from that of the clinical laboratory. All such paths of workflow describe the sequence of activities necessary to produce the organization's or an entity's specific product or services. For those documents that relate to other paths of workflow, the icon will reflect different process steps.

**C30-A2 Addresses the Following Steps Within the Clinical Laboratory Path of Workflow**

Preanalytical					Analytical		Postanalytical	
Patient Assessment	Test Request	Specimen Collection	Specimen Transport	Specimen Receipt	Testing Review	Laboratory Interpretation	Results Report	Post-test Specimen Management
X		X			X		X	

Adapted from NCCLS document HS1—*A Quality System Model for Health Care*



## Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline—Second Edition

### 1 Introduction

Point-of-care (POC) blood glucose testing, as performed by trained personnel in acute and chronic care facilities, provides rapid blood glucose results that are used by medical staff members to make therapeutic decisions. In providing this service, the institution assumes a commitment to maintain high-quality POC blood glucose testing and effective methods for communicating the results to appropriate patient-care providers.

There is a need for specific guidelines and policies for POC blood glucose testing due to the unique characteristics of this activity. POC blood glucose testing often requires the coordination and cooperation of multiple departments, training of operators with limited laboratory training, and use of specimens and technologies that differ from those used by laboratories.

#### 1.1 Scope

This guideline provides instructions and recommendations concerning the administration of POC blood glucose monitoring programs at acute and chronic care facilities where laboratory support is available. POC blood glucose monitoring systems provide rapid results required by medical staff members to make therapeutic decisions. For facilities where laboratory support is not available, refer to NCCLS document *AST4—Blood Glucose Testing in Settings Without Laboratory Support*.

This document applies to quantitative *in vitro* POC whole blood glucose monitoring systems intended for use by healthcare professionals for management of patients with diabetes mellitus and other conditions with perturbations in glucose homeostasis. These test systems may be indicated for use with arterial, venous, or capillary whole blood samples obtained from adults, children, or neonates. This guideline does not pertain to glucose measurement for the purpose of screening for diabetes or diagnosing diabetes mellitus or other disorders of glucose metabolism.

Laboratory clinical chemistry analyzers or dedicated systems used to perform routine and stat glucose testing on plasma, serum, whole blood, urine, and cerebrospinal fluid are not included in the scope of this guideline.

### 2 Definitions<sup>a</sup>

**Authorization, *n*** - Recognition of a person who has satisfied the qualification requirements to perform POC blood glucose testing within an institution.

**Competency, *n*** - Following successful completion of a training program, the assessment of a person's ability to perform POC blood glucose testing.

**Director, *n*** - The person designated as having primary responsibility for the POC blood glucose testing service.

**Instrument verification, *n*** - A documented procedure for ensuring that POC blood glucose testing instruments are performing according to the manufacturer's established criteria.

---

<sup>a</sup> Some of these definitions are found in NCCLS document NRSL8—*Terminology and Definitions for Use in NCCLS Documents*. For complete definitions and detailed source information, please refer to the most current edition of that document.